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ABSTRACT Enterococci are ancient commensal bacteria that recently emerged as lead-
ing causes of antibiotic-resistant, hospital-acquired infection. Vancomycin-resistant en-
terococci (VRE) epitomize why drug-resistant enterococcal infections are a problem:
VRE readily colonize the antibiotic-perturbed gastrointestinal (GI) tract where they
amplify to large numbers, and from there, they infect other body sites, including the
bloodstream, urinary tract, and surgical wounds. VRE are resistant to many antimi-
crobials and host defenses, which facilitates establishment at the site of infection
and confounds therapeutic clearance. Having evolved to colonize the GI tract, VRE
are comparatively ill adapted to the human bloodstream. A recent study by Honsa
and colleagues (E. S. Honsa et al., mBio 8:e02124-16, 2017, https://doi.org/10.1128/
mBio.02124-16) found that a strain of vancomycin-resistant Enterococcus faecium
evolved antibiotic tolerance within the bloodstream of an immunocompromised
host by activating the stringent response through mutation of relA. Precisely how
VRE colonize and infect and the selective pressures that led to the outgrowth of relA
mutants are the subjects of ongoing research.
Bacteria in the genus Enterococcus occur among the intestinal consortia of hosts thatspan the animal kingdom (1). These intrinsically rugged bacteria have become
leading multidrug-resistant hospital pathogens. The enterococci are among the van-
guard of antibiotic-resistant bacteria for at least two reasons: they evolved in the
gastrointestinal (GI) tracts of insects and other invertebrates that naturally live and feed
on organic matter that contains antibiotics and antibiotic-producing microorganisms
(2), and they are naturally hardy and are able to withstand starvation, desiccation, and
other stresses better than most other microbes. Enterococci are intrinsically resistant to
many antibiotics, and they readily mutate or acquire resistance genes to others as
needed. In addition to being leading multidrug-resistant hospital pathogens, they also
serve as reservoirs and transmit resistance genes to other bacteria. Enterococcus fae-
cium and Enterococcus faecalis are the enterococcal species most often associated with
multidrug-resistant nosocomial infection, and about 30 years ago, both species ac-
quired resistance to the important last-line bactericidal drug, vancomycin.
Vancomycin-resistant enterococci (VRE) pose a special threat to immunocompro-
mised patients, who often undergo antibiotic treatment or prophylaxis in hospitals. The
study by Honsa and colleagues (3) describes the evolution of a vancomycin-resistant
E. faecium strain within such a patient. How did this pediatric patient become infected
with VRE? Nearly all VRE infections begin with colonization of the GI tract by bacteria
that are ingested from the hospital environment (Fig. 1). Enterococci are resistant to
desiccation and starvation, and they are difﬁcult to eradicate from the hospital with
disinfectants (1). From contaminated patient-proximal surfaces, including bed rails and
thermometer handles, enterococci survive transit through the stomach and small
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intestine, and then they replicate in the large intestine where they may reach very high
densities due to limited competition because of prior antibiotic treatment. Dense
intestinal colonization with VRE recontaminates the patient-proximal environment,
perpetuating its presence within modern hospitals (4). The risk of developing a VRE
infection is very likely directly proportional to the number of drug-resistant enterococci
in the GI tract; more colonization equals greater risk of infection.
The patient described in this study (3) was uniquely susceptible to vancomycin-
resistant E. faecium colonization and infection. Only 6 weeks old, she had an immature
GI tract microbiome, which was further confounded by chemotherapy to treat acute
myeloid leukemia, causing impaired host defenses, accompanied by antibiotic treat-
ment. Among the agents used was a broad-spectrum cephalosporin, to which entero-
cocci are intrinsically resistant, and which prior work has shown limits the occurrence
of competing commensal anaerobes (5–7). The VRE that colonized the patient’s GI tract
most likely seeded her bloodstream, but whether that occurred through translocation
through the gut wall, which often becomes inﬂamed during chemotherapy (8) or from
contaminants that made their way to the skin and were introduced into the blood-
stream through the central venous catheter is unclear.
It was recently shown that hospital-adapted, multidrug-resistant strains of E. faecium
belong to a distinct lineage (clade A) that diverged from human commensal strains
(clade B) of the species approximately 3,000 years ago (9). The lineage of hospital-
adapted E. faecium, known as clade A1 or clonal cluster 17 (CC17), is so different from
commensal strains that an argument can be made that they should be considered a
different species entirely (9). The VRE strain studied by Honsa et al. (3), in fact belongs
to clade A1/CC17, which is globally disseminated. Genetic factors enriched in this
hospital-adapted E. faecium clade include the following: (i) altered cell wall polysac-
charide and capsule biosynthesis genes that appear to enhance its ﬁtness for the
hospital environment (10); (ii) an accumulation of mobile elements likely due to a
FIG 1 Simpliﬁed model of bacterial population dynamics during VRE colonization, infection, and
selection of relA mutants in an immunocompromised patient. Bacteria, including VRE, are ﬁrst ingested
from the patient-proximal hospital environment. Transit through the upper GI tract coupled with
broad-spectrum antibiotic treatment kill off nearly all other microbes, allowing VRE to grow to very high
densities in the lower GI tract. A small number of bacteria from the GI tract population seed the
bloodstream, where the population expands again. Once a relA mutant bacterium occurs in the
bloodstream VRE population, it is able to grow to a high enough density to be detected, because it
provides a survival advantage against antibiotic treatment, nutrient limitation, and/or oxidative stress.
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missing clustered regularly interspaced short palindromic repeat (CRISPR)-Cas system
(9, 11); and (iii) a unique phosphotransferase system (PTS) that allows for the utilization
of amino sugars, which occur on epithelial cell surfaces and mucin. This PTS has been
shown to enhance the ability of E. faecium to colonize the antibiotic-perturbed GI tract
(12), and suggests that hospital-adapted VRE strains adopt a parasitic lifestyle, feeding
on host-derived secretions, such as mucin, when other dietary carbohydrates are not
available.
By sequencing the genomes of 22 consecutive bloodstream VRE isolates from the
same patient, Honsa and colleagues (3) were able to identify mutations that occurred
during infection and growth in blood, an environment to which enterococci are not
naturally adapted. A mutation in relA was repeatedly seen in 8 of the 22 isolates, so the
authors investigated possible biological consequences of this mutation. They found
that relA mutant strains constitutively activated the stringent response through ele-
vated baseline levels of the alarmone (p)ppGpp. The relA mutant strains were not more
drug resistant as deﬁned by the ability to grow planktonically in higher levels of drug,
but in bioﬁlms, the mutant strains showed greater tolerance to lethal doses of both
linezolid and daptomycin. Enigmatically, bioﬁlms formed by the relA mutants were less
adherent and more sparsely populated under the conditions studied.
The authors suggest that antibiotic use may have provided the selective pressure that
led to the outgrowth of relAmutant strains. The adaptation of enterococci to growth in the
bloodstream is complex, and the selective pressure or pressures may be more complex
than initially thought. Daptomycin has been shown to select for relAmutations in vitro (13),
and daptomycin treatment in this patient may have helped sustain the relA mutants at a
high frequency in the population. Nevertheless, daptomycin could not have been the
original selective pressure that drove the mutation to a high enough level to be detected
in the ﬁrst place, because the initial relA mutant was isolated a week prior to daptomycin
therapy. Other antibiotics given to the patient preceding the appearance of the relA
mutation were cefepime, vancomycin, meropenem, and linezolid. Of these antibiotics,
vancomycin is known to have the ability to induce the stringent response (14); however,
this strain was already highly vancomycin resistant and was likely inert to the effects of the
drug. Use of beta-lactams and linezolid have been shown to be associated with relA
mutations in Staphylococcus aureus (15, 16), but these drugs do not appear to directly
induce the stringent response. Indeed, Honsa and colleagues found that linezolid exposure
did not increase (p)ppGpp levels in the wild-type strain (3).
What besides antibiotic pressure may have selected for activation of the stringent
response in this patient? First, nutrient limitation is well-known to activate the stringent
response (17). While blood may not seem like a nutrient-limited environment, nutrient
withholding is a key component of innate immunity (18), and the nutrient proﬁle of
blood differs substantially from that of the GI tract. Enterococci therefore need to alter
their metabolism and physiology considerably to grow efﬁciently in the bloodstream.
Second, exposure to reactive oxygen species during bacterial engulfment by immune
cells of an immunologically normal host, and possibly with residual function in this
infant receiving chemotherapy, is a potent activator of the stringent response (17).
Could one or more of these mechanisms have selected for constitutive stringent
response expression by the VRE isolated from the pediatric patient studied by Honsa
and colleagues (3)? Despite severe neutropenia and bone marrow that was not
producing functional immune cells due to chemotherapy, tissue-resident macrophages
may still have been present and functioning (19). Overall, our understanding of how
VRE adapt to nutrient limitation, antibiotic pressure, and oxidative stress in blood-
stream infections is far from complete, and which of these may have selected for the
outgrowth of bacteria with relA mutations in this case remains highly speculative.
Regardless of the pressure or pressures that selected for them, the relA mutants
were unable to completely displace the wild-type strain within the bloodstream of this
patient. Only 8 of the 22 isolates collected possessed the relA mutation, and wild-type
strains were isolated throughout the course of the infection. Honsa and colleagues (3)
showed that the relA mutants were compromised in their ability to form bioﬁlms; this
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ﬁnding demonstrates how context matters when assessing whether a mutation is
beneﬁcial or not. In the face of cellular stresses, such as those described above,
mutating relA in order to accumulate (p)ppGpp appears to be beneﬁcial. However, in
other situations, such as needing to compete for resources in order to grow and persist
in the bloodstream, the same mutation is likely detrimental. For the population as a
whole, it seems that retaining a mixture of wild-type and relA mutant bacteria might
have offered the best of both worlds.
Ultimately, bloodstream infection with VRE is likely an evolutionary dead end for the
bacteria. Because VRE are transmitted between patients by the fecal-oral route, bacteria
growing in the bloodstream are highly unlikely to ﬁnd their way into a subsequent
patient. Thus, bacteria must “relearn” how to grow within the bloodstream of each new
patient that they infect. Honsa and colleagues (3) show that activation of the stringent
response is an advantageous adaptation in the bloodstream of an immunocompro-
mised host, and this is the ﬁrst study to document an E. faecium strain evolving a relA
mutation in vivo. Future surveillance will determine whether this adaptation is generally
encountered in enterococcal bacteremia or whether the outgrowth of these mutants
was unique to the ecological conditions present in the bloodstream of this infant.
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